DOI: http://dx.doi.org/10.18203/2349-3933.ijam20182072

Epidermal growth factor receptor protein expression in lung cancer and survival analysis

Shivalingaswamy Salimath, Jayaraj B. S., Mahesh P. A., M. D. Majeed Pasha, Lokesh K. S., Mahendra M.

Abstract


Background: Epidermal Growth Factor Receptor (EGFR) is one of the important molecules involved in lung cancer initiation and progression. Studies on over expression of EGFR and its survival in relation with Non-small cell lung cancer (NSCLC) patients have yielded controversial results. Prevalence of EGFR expression in NSCLC patients and 6-month survival in south Indian population is unknown.

Methods: We carried out a prospective study in tertiary hospital. Diagnosed patients with NSCLC were included in the study and were interviewed with questionnaire containing demography and investigations like Chest X-ray, CT thorax, Bronchoscopy were recorded. EGFR expression analysis was done for all patients and were followed up monthly for 6 months and details of survival and treatment were collected. Cox regression analysis was used to assess their survival.

Results: 50 patients with NSCLC were included. Forty-four (88%) were men, median age of study group was 65 years. Twenty-seven patients (54%) had Adenocarcinoma, 14 patients (28%) had Squamous cell carcinoma, 7 patients (14%) had poorly differentiated carcinoma and 2 patients (4%) had large cell carcinoma. Thirty-four (68%) samples were positive for EGFR expression. On multivariate analysis we found patients who took chemotherapy and with good performance status (Karnofsky score >65 and Eastern Cooperative Oncology Group >2.5) had better survival at 6 months.

Conclusions: Patients with EGFR positivity had better survival with chemotherapy but worse with radiotherapy. Patients who took chemotherapy and had good performance status had better survival on multivariate analysis. We didn’t find any correlation between EGFR positivity and poor survival.


Keywords


Chemotherapy, EGFR, Lung cancer, NSCLC, Survival

Full Text:

PDF

References


WHO | Cancer. In: WHO. http://www.who.int/mediacentre/factsheets/fs297/en/.

Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA oncology. 2017;3:524-48.

Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10:4227s-32s.

D'amico TA, Massey M, Herndon II JE, Moore MB, Harpole DH. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg.1999;117:736-43.

Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 2005;23:3235-42.

Prime SS, Game SM, Matthews JB, Stone A, Donnelly MJ, Yeudall WA, Patel V, et al Epidermal growth factor and transforming growth factor alpha characteristics of human oral carcinoma cell lines. Br J Cancer.1994;69:8-15.

Giatromanolaki A, Koukourakis MI, O'Byrne K, Kaklamanis L, Dicoglou C, Trichia E et al Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res.1996;16:3819-25.

Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, et al Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998;4:241-9.

Cox G, Jones JL, O’Byrne KJ. Matrix Metalloproteinase 9 and the Epidermal Growth Factor Signal Pathway in Operable Non-Small Cell Lung Cancer. Clin Cancer Res. 2000;6:2349-55.

What Is Non-Small Cell Lung Cancer? https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html.

Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, et al Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2004;15:28-32.

Protein overexpression and gene amplification of epidermal growth factor receptor in non-small cell lung carcinomas - Suzuki - 2005 - Cancer - Wiley Online Library. http://onlinelibrary.wiley.com/doi/10.1002/cncr.20909/abstract.

Doval DC, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid AK, et al Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Onco Targets Ther 2015;8:117-23.

Mahesh PA, Archana S, Jayaraj BS, Patil S, Chaya SK, Shashidhar HP. Factors affecting 30-month survival in lung cancer patients. Indian J Med Res. 2012;136:614-21.

Ahn JH, Kim SW, Hong SM, Suh C, Kim WK, Lee IC, et al Epidermal Growth Factor Receptor (EGFR) Expression in Operable Non-small Cell Lung Carcinoma. J Korean Med Sci. 2004;19:529-35.

Shah L, Walter KL, Borczuk AC, Kawut SM, Sonett JR, Gorenstein LA Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer. 2004;101:1632-8.

Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G et al Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. Cancer Chemother Pharmacol. 2013;71:671-80.

Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, Beck A, et al Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol. 2004;17:430-9.

Ahn J-H, Kim S-W, Hong S-M, et al (2004) Epidermal Growth Factor Receptor (EGFR) Expression in Operable Non-small Cell Lung Carci. J Korean Med Sci. 2004;19:529-35.

Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, et al KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer. 2010;69:272-8.

Van Dyke AL, Cote ML, Prysak GM, Claeys GB, Wenzlaff AS, Murphy VC, et al COX-2/EGFR expression and survival among women with adenocarcinoma of the lung. Carcino 2008;29:1781-87.

Ucvet A, Kul C, Gursoy S, Erbaycu AE, Kaya SO, Dinc ZA et al (2011) Prognostic Value of Epithelial Growth Factor Receptor, Vascular Endothelial Growth Factor, E-Cadherin, and p120 Catenin in Resected Non-Small Cell Lung Carcinoma. Arch Bronconeumol Eng Ed. 2011;47:397-402.

Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3:515-22.

Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. “The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Euro Resp J. 2002;20:975-81.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New Eng J Med. 2009;361:947-57.

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:2866-74.

Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, et al Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet Eng. 2005;366:1527-37.

Hirsch FR, Varella-Garcia M, Bunn Jr PA, Di Maria MV, Veve R, Bremnes RM et al Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3798-807.

Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys. 2004:58:966-71.

Radzikowska E, Roszkowski-Sliz K, Chabowski M, Glaz P. Influence of delays in diagnosis and treatment on survival in small cell lung cancer patients. 2013. Adv Exp Med Biol.2013;788:355-62.

Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2005;16:780-5.